Legend Biotech Corporation

NASDAQ:LEGN

Biotechnology

Healthcare
$16.25 -13.51%

-$4.53 today

Market cap
$3.01B
Beta
0.35
P/E (TTM)
-21.4
EPS (TTM)
-$1.35
52W Low $16.24High $45.30

Volume 2.15M

Average 2.42M

LEGN Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Legend Biotech CorporationNASDAQ: LEGN

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q3 FY2026 depreciation & amortization of $11M rose 87.1% year over year, behind the +111.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.

Context

  • Depreciation & amortization amounted to 2.8% of revenue in FY2025, down 0.9 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +87.1% toward the trailing-twelve-month pace of +111.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$11M-6.0% QoQ
Last fiscal yearDec 2025
$28.9M+23.7% YoY
LTMSep 2026
$50.27M+111.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+87.1%——
1 year+23.7%——
3-year CAGR+16.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
28.9M USD
Year-over-year change
+23.7%
4-year CAGR
+20.0%

Depreciation & Amortization vs competitors

How LEGN compares with its peers on the latest reported figures

  • LEGN's LTM Sep 2026 depreciation & amortization of $50.27M is the highest of the 11 companies compared; the peer median is $11.28M.
  • Its year-over-year change of +111.9% is the highest of 11, against a peer median of -18.3%.
  • Depreciation & amortization amounts to 3.7% of revenue for LEGN, versus a peer median of 28.4%.
LEGN Competitors Peer median
Depreciation & Amortization for LEGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$50.27M +111.9%+16.3%3.7%
CLLSCellectis S.A.LTM Mar 2026$19.68M -2.6%+2.9%28.9%
AUTLAutolus Therapeutics plcLTM Mar 2026$13M +24.1%+9.8%14.0%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$12.88M -3.1%+15.8%—
FATEFate Therapeutics, Inc.LTM Mar 2026$12.49M -28.5%-12.3%197.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$12.13M -8.0%-4.7%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M -42.2%-13.8%33645.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$3.13M -28.6%+0.0%27.9%
DTILPrecision BioSciences, Inc.LTM Mar 2026$2.69M -30.3%-32.6%6.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$2.42M +13.8%+13.3%136.2%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$350K -93.6%-27.9%1.5%
Peer median (excluding LEGN) $11.28M-18.3%-2.3%28.4%

Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.83M117.01M285.14M627.24M1.03B
Cost of Revenue065.36M144.21M234.58M408.1M
Gross Profit68.83M51.64M140.93M392.66M620.8M
Gross Margin100.0%44.1%49.4%62.6%60.3%
Research & Development313.35M335.65M382.22M413.54M414.7M
Selling, General & Admin149.5M174.05M200.93M284.26M341.6M
Operating Expenses461.11M507.26M580.41M695.9M757.3M
Depreciation & Amortization13.92M18.39M20.45M23.36M28.9M
EBITDA(392.38M)(416.54M)(477.87M)(113.16M)(232.3M)
EBITDA Margin-570.1%-356.0%-167.6%-18.0%-22.6%
Operating Income(392.29M)(455.62M)(439.49M)(303.24M)(136.5M)
Operating Margin-570.0%-389.4%-154.1%-48.3%-13.3%
Interest Income971K8.18M54.49M61.2M40.1M
Interest Expense900K10.8M21.79M21.62M21.4M
Other Income / Expenses(14.91M)9.9M(80.63M)145.11M(146.1M)
Income Before Tax(407.2M)(445.72M)(520.12M)(158.13M)(282.6M)
Pre-Tax Margin-591.6%-380.9%-182.4%-25.2%-27.5%
Income Tax Expense(3.61M)625K(1.86M)18.89M14.2M
Net Income(403.58M)(446.35M)(518.25M)(177.03M)(296.8M)
Net Margin-586.4%-381.5%-181.8%-28.2%-28.8%
EPS (Basic)(2.74)(2.81)(2.94)(0.97)(1.60)
EPS (Diluted)(2.74)(2.81)(2.94)(0.97)(1.60)
Weighted Avg Shares140.85M159.04M176.08M182.85M184.32M
Weighted Avg Shares (Diluted)140.85M159.04M176.08M182.85M184.32M

Legend Biotech Corporation

NASDAQ:LEGN

Intrinsic Alpha fair value

Locked

Current Price

$16.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.